LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of …
J Bourhis, C Sire, Y Tao, L Martin, M Alfonsi… - Annals of …, 2020 - annalsofoncology.org
Background Based on the hypothesis of a potential synergistic effect of the anti-PD1
pembrolizumab when combined with RT, this new combination was tested in a randomized …
pembrolizumab when combined with RT, this new combination was tested in a randomized …
A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head …
XS Sun, C Sire, Y Tao, L Martin, M Alfonsi, JB Prevost… - 2018 - ascopubs.org
6018 Background: Based on the hypothesis of a potential synergistic effect of the anti-PD1
pembrolizumab when combined with RT, this new combination was tested in a phase II …
pembrolizumab when combined with RT, this new combination was tested in a phase II …
LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced …
JP Machiels, Y Tao, B Burtness, M Tahara… - Annals of …, 2022 - annalsofoncology.org
Background Pembro is approved as monotherapy or in combination with chemotherapy for
recurrent/metastatic HNSCC. The randomized, double-blind, phase 3 KEYNOTE-412 …
recurrent/metastatic HNSCC. The randomized, double-blind, phase 3 KEYNOTE-412 …
LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN) …
Background Based on a potential synergistic effect of anti–PD-L1 avelumab plus cetuximab
and radiotherapy (RT), this combination was tested in a randomized phase III trial against 2 …
and radiotherapy (RT), this combination was tested in a randomized phase III trial against 2 …
[HTML][HTML] Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin …
Background To evaluate potential synergistic effect of pembrolizumab with radiotherapy
(RT) compared with a standard-of-care (SOC) cetuximab–RT in patients with locally …
(RT) compared with a standard-of-care (SOC) cetuximab–RT in patients with locally …
Safety of pembrolizumab with chemoradiation (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
SF Powell, MM Gitau, CJ Sumey, JT Reynolds, M Lohr… - 2017 - ascopubs.org
6011 Background: Pembrolizumab (pembro) is a humanized monoclonal antibody that
blocks the programmed death receptor-1 (PD-1) interaction with its ligands (PD-L1, PD-L2) …
blocks the programmed death receptor-1 (PD-1) interaction with its ligands (PD-L1, PD-L2) …
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412
JP Machiels, Y Tao, B Burtness, M Tahara… - Future …, 2020 - Taylor & Francis
Current treatment guidelines for patients with locally advanced head and neck squamous
cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation …
cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation …
[HTML][HTML] Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a …
Y Tao, A Aupérin, X Sun, C Sire, L Martin… - European journal of …, 2020 - Elsevier
Background Based on the hypothesis of synergistic effect of avelumab with cetuximab and
radiotherapy, this new combination is tested in a randomised trial against two well …
radiotherapy, this new combination is tested in a randomised trial against two well …
910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients …
Background Despite high-dose, cisplatin-containing, multimodality therapy, LA SCCHN
ultimately recurs in many patients. This trial investigated whether avelumab, a human anti …
ultimately recurs in many patients. This trial investigated whether avelumab, a human anti …
Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a phase IB study
SF Powell, KA Gold, MM Gitau, CJ Sumey… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Pembrolizumab is a humanized monoclonal antibody that blocks interaction
between programmed death receptor-1 (PD-1) and its ligands (PD-L1, PD-L2). Although …
between programmed death receptor-1 (PD-1) and its ligands (PD-L1, PD-L2). Although …
相关搜索
- concomitant with radiotherapy cell carcinoma
- chemoradiotherapy in locally advanced head
- head and neck standards of care
- head and neck randomized phase
- stage head cell carcinoma
- cetuximab and avelumab cell carcinoma
- pembrolizumab with chemoradiotherapy cell carcinoma
- efficacy of pembrolizumab cell carcinoma
- head and neck safety of pembrolizumab
- immuno radiotherapy cell carcinoma
- head and neck chemoradiation crt
- maintenance therapy cell carcinoma
- safety and efficacy cell carcinoma
- standards of care cell carcinoma
- head and neck cetuximab radiotherapy
- cetuximab radiotherapy cell carcinoma